-
Je něco špatně v tomto záznamu ?
DNA methylation and hydroxymethylation patterns in acute myeloid leukemia patients with mutations in DNMT3A and IDH1/2 and their combinations
Š. Šestáková, Z. Krejčík, A. Folta, E. Cerovská, C. Šálek, MD. Merkerová, P. Pecherková, Z. Ráčil, J. Mayer, P. Cetkovský, H. Remešová,
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články
Grantová podpora
NV15-25809A
MZ0
CEP - Centrální evidence projektů
Digitální knihovna NLK
Plný text - Článek
Zdroj
NLK
Medline Complete (EBSCOhost)
od 2005-01-01 do Před 9 měsíci
PubMed
30988238
DOI
10.3233/cbm-182176
Knihovny.cz E-zdroje
- MeSH
- akutní myeloidní leukemie genetika metabolismus MeSH
- DNA-(cytosin-5-)methyltransferasa genetika MeSH
- granzymy genetika MeSH
- isocitrátdehydrogenasa genetika MeSH
- leukocyty mononukleární metabolismus MeSH
- lidé středního věku MeSH
- lidé MeSH
- metylace DNA * MeSH
- mutace MeSH
- prognóza MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- stanovení celkové genové exprese MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
BACKGROUND: Aberrant epigenetic patterns are a hallmark of acute myeloid leukemia (AML). Mutations in profound epigenetic regulators DNMT3A and IDH1/2 often occur concurrently in AML. OBJECTIVES: The aim was to analyze DNA methylation, hydroxymethylation and mRNA expression profiles in AML with mutations in DNMT3A and IDH1/2 (individually and in combinations). METHODS: Infinium MethylationEPIC BeadChip (Illumina) covering 850,000 CpGs was utilized. The validation of hydroxy-/methylation data was done by pyrosequencing. HumanHT-12 v4 Expression BeadChip (Illumina) was used for expression examination. RESULTS: Hierarchical clustering analysis of DNA hydroxy-/methylation data revealed clusters corresponding to DNMT3A and IDH1/2 mutations and CD34+ healthy controls. Samples with concurrent presence of DNMT3A and IDH1/2 mutations displayed mixed DNA hydroxy-/methylation profile with preferential clustering to healthy controls. Numbers and levels of DNA hydroxymethylation were low. Uniformly hypermethylated loci in AML patients with IDH1/2 mutations were enriched for immune response and apoptosis related genes, among which hypermethylation of granzyme B (GZMB) was found to be associated with inferior overall survival of AML patients (P= 0.035). CONCLUSIONS: Distinct molecular background results in specific DNA hydroxy-/methylation profiles in AML. Site-specific DNA hydroxymethylation changes are much less frequent in AML pathogenesis compared to DNA methylation. Methylation levels of enhancer located upstream GZMB gene might contribute to AML prognostication models.
Department of Internal Medicine Hematology and Oncology University Hospital Brno Brno Czech Republic
Institute of Hematology and Blood Transfusion Prague Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19044878
- 003
- CZ-PrNML
- 005
- 20231102133507.0
- 007
- ta
- 008
- 200109s2019 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3233/CBM-182176 $2 doi
- 035 __
- $a (PubMed)30988238
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Šestáková, Šárka $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
- 245 10
- $a DNA methylation and hydroxymethylation patterns in acute myeloid leukemia patients with mutations in DNMT3A and IDH1/2 and their combinations / $c Š. Šestáková, Z. Krejčík, A. Folta, E. Cerovská, C. Šálek, MD. Merkerová, P. Pecherková, Z. Ráčil, J. Mayer, P. Cetkovský, H. Remešová,
- 520 9_
- $a BACKGROUND: Aberrant epigenetic patterns are a hallmark of acute myeloid leukemia (AML). Mutations in profound epigenetic regulators DNMT3A and IDH1/2 often occur concurrently in AML. OBJECTIVES: The aim was to analyze DNA methylation, hydroxymethylation and mRNA expression profiles in AML with mutations in DNMT3A and IDH1/2 (individually and in combinations). METHODS: Infinium MethylationEPIC BeadChip (Illumina) covering 850,000 CpGs was utilized. The validation of hydroxy-/methylation data was done by pyrosequencing. HumanHT-12 v4 Expression BeadChip (Illumina) was used for expression examination. RESULTS: Hierarchical clustering analysis of DNA hydroxy-/methylation data revealed clusters corresponding to DNMT3A and IDH1/2 mutations and CD34+ healthy controls. Samples with concurrent presence of DNMT3A and IDH1/2 mutations displayed mixed DNA hydroxy-/methylation profile with preferential clustering to healthy controls. Numbers and levels of DNA hydroxymethylation were low. Uniformly hypermethylated loci in AML patients with IDH1/2 mutations were enriched for immune response and apoptosis related genes, among which hypermethylation of granzyme B (GZMB) was found to be associated with inferior overall survival of AML patients (P= 0.035). CONCLUSIONS: Distinct molecular background results in specific DNA hydroxy-/methylation profiles in AML. Site-specific DNA hydroxymethylation changes are much less frequent in AML pathogenesis compared to DNA methylation. Methylation levels of enhancer located upstream GZMB gene might contribute to AML prognostication models.
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a DNA-(cytosin-5-)methyltransferasa $x genetika $7 D004248
- 650 12
- $a metylace DNA $7 D019175
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a stanovení celkové genové exprese $7 D020869
- 650 _2
- $a granzymy $x genetika $7 D053804
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a isocitrátdehydrogenasa $x genetika $7 D007521
- 650 _2
- $a akutní myeloidní leukemie $x genetika $x metabolismus $7 D015470
- 650 _2
- $a leukocyty mononukleární $x metabolismus $7 D007963
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a mutace $7 D009154
- 650 _2
- $a prognóza $7 D011379
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Krejčík, Zdeněk $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
- 700 1_
- $a Folta, Adam $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic.
- 700 1_
- $a Cerovská, Ela $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
- 700 1_
- $a Šálek, Cyril $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
- 700 1_
- $a Merkerová, Michaela Dostálová $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
- 700 1_
- $a Pecherková, Pavla, $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic. $d 1980- $7 ctu2013787641
- 700 1_
- $a Ráčil, Zdeněk $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic. Department of Internal Medicine, Hematology and Oncology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Mayer, Jiří $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic. Department of Internal Medicine, Hematology and Oncology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Cetkovský, Petr $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
- 700 1_
- $a Remešová, Hana $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
- 773 0_
- $w MED00173146 $t Disease markers. Section A, Cancer Biomarkers $x 1875-8592 $g Roč. 25, č. 1 (2019), s. 43-51
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30988238 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20200109 $b ABA008
- 991 __
- $a 20231102133502 $b ABA008
- 999 __
- $a ok $b bmc $g 1483147 $s 1083551
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 25 $c 1 $d 43-51 $e - $i 1875-8592 $m Disease markers. Section A, Cancer Biomarkers $n Cancer Biomark $x MED00173146
- GRA __
- $a NV15-25809A $p MZ0
- LZP __
- $a Pubmed-20200109
